Castleview Partners’s Opko Health OPK Stock Holding History

Castleview Partners’s Portfolio OPK Stock Details OPK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-3,000	Closed	-$3.75K	–	797
2024 Q2	$3.75K	Sell	3,000 -19,951	-87%	-$25.9K	﹤0.01%	658
2024 Q1	$27.5K	Hold	22,951	–	–	0.02%	425
2023 Q4	$34.7K	Sell	22,951 -10,500	-31%	-$15.2K	0.02%	364
2023 Q3	$53.5K	Hold	33,451	–	–	0.05%	246
2023 Q2	$72.6K	Hold	33,451	–	–	0.07%	216
2023 Q1	$48.8K	Hold	33,451	–	–	0.04%	267
2022 Q4	$41.8K	Hold	33,451	–	–	0.04%	245
2022 Q3	$63K	Buy	33,451 +32,965	+6,783%	+$77.9K	0.06%	219
2022 Q2	$34K	Sell	486 -32,965	-99%	-$96.1K	0.03%	344
2022 Q1	$115K	Buy	33,451 +16,616	+99%	+$58.7K	0.07%	218
2021 Q4	$3.5K	Buy	+16,835	New	+$68.1K	0.03%	204
2021 Q2	$135K	Buy	+33,451	New	+$131K	0.06%	247
2018 Q1	$103K	Buy	+32,451	New	+$131K	0.09%	113

Other funds holding OPK

RCMNY

Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Castleview Partners's OPK Position: Q3 2024 in Review

Castleview Partners sold out of Opko Health (OPK) in Q3 2024, closing a stake of 3,000 shares — an estimated $3.75K sold.

Castleview Partners first reported a position in OPK in Q1 2018 and held it in 13 quarters. The position peaked at $135K in Q2 2021. 234 funds tracked by Wall St. Rank hold OPK as of Q3 2024.

Castleview Partners reported no remaining Opko Health position as of Q3 2024 after selling out during the quarter.
Castleview Partners sold 3,000 Opko Health shares in Q3 2024, an estimated $3.75K.
Castleview Partners first reported a position in Opko Health in Q1 2018 and held it in 13 quarters.
Castleview Partners's Opko Health position peaked at $135K in Q2 2021.
234 funds tracked by Wall St. Rank held Opko Health as of Q3 2024.

Based on Castleview Partners's 13F filing for Q3 2024, filed 9 Oct 2024.